Purity ≥ 98%
Rigorous analytical processes ensure high purity in every batch.
SCIENCE THAT TRANSFORMS
Complete Line of High-Purity Peptides
Advanced research. Real results. Every formula developed with scientific precision, exceptional purity, and pharmaceutical rigor.
≥ 98%PURITY
10+PEPTIDES
USAMANUFACTURING
GMPSTANDARD
TECHNOLOGY
A peptide platform built for precise results
Our peptide synthesis uses advanced solid-phase chemistry, ensuring ≥98% purity in every batch produced in the United States.
Every batch undergoes HPLC analysis and mass spectrometry, ensuring identity, purity, and consistency for reliable research.
THE NEXA ADVANTAGE
Molecular precision in every peptide
Explore selected structures from our line and discover the standards that guide every batch.
GHK-CuGly-His-Lys · Cu²⁺
Controlled lyophilization
Stability and integrity preserved through precision drying.
Made in the USA
Produced in specialized facilities following GMP standards.
Verified molecular structure
Identity confirmed by HPLC and mass spectrometry.
COMPLETE LINE
Peptides for advanced research
Select a product to explore its structure and specifications.
GHK-CuGly-His-Lys · Cu²⁺
COPPER PEPTIDE
GHK-Cu
Gly-His-Lys · Cu²⁺
CONCENTRATION10 mg
FORMLyophilized
PURITY≥ 98%
ANALYSISHPLC + MS
MANUFACTURINGUnited States
STANDARDGMP
High-purity copper peptide (Glycyl-L-Histidyl-L-Lysine Copper) for research into cellular renewal, collagen synthesis, and skin, hair, and tissue health.
Refrigerated2–8 °CProtected from light
ABOUT NEXA PHARMA
A decade at the forefront of peptide science
Nexa Pharma was founded in 2016 by scientists and physicians specializing in biochemistry and pharmacology, united by the belief that peptides would define the next major therapeutic frontier. We invested in science before regulation, building research and synthesis infrastructure capable of producing true pharmaceutical-grade compounds.
Over nearly a decade, we have established partnerships with GMP-certified laboratories in the United States and developed rigorous HPLC and mass spectrometry analysis protocols for researchers and healthcare professionals who expect more.
We closely monitor the U.S. regulatory process. In April 2026, 12 peptides—including BPC-157, TB-500, MOTS-C, and GHK-Cu—were removed from the FDA Category 2 compounding restriction list. The Pharmacy Compounding Advisory Committee is scheduled to begin reassessment in July 2026.
Nexa Pharma founded
A multidisciplinary founding group establishes the mission of true pharmaceutical-grade peptide synthesis.
First GMP-certified line
Partnership established with a U.S. GMP-certified laboratory, with complete traceability and mandatory HPLC analysis.
Peptide line expansion
Eight compounds launched with ≥98% purity confirmed by mass spectrometry and amino-acid sequencing.
FDA regulatory monitoring
Formal monitoring of the FDA review process begins for compounds in our research line.
FDA PCAC regulatory milestone
Twelve peptides are removed from Category 2; a reassessment meeting is scheduled for July 2026.
FDA approval in progress
Nexa Pharma is positioned to adapt immediately as formal approvals advance.
OUR TEAM
Experts turning science into precision
DR
Dr. Richard Almeida
Scientific DirectorPhD in Biochemistry — Johns Hopkins University
15 years in therapeutic peptide synthesis
18 publications in indexed journals
SM
Dr. Sarah Mitchell
Director of Regulatory AffairsPharmD — University of California, San Francisco
Former FDA consultant — Pharmacology Division
503A/503B process specialist
JK
Dr. James Kovalev
Head of R&DPhD in Pharmacology — MIT
Postdoctoral research in mitochondrial peptides — NIH
Co-author of research on MOTS-C and SS31
LC
Dr. Laura Chen
Director of Quality ControlPhD in Analytical Chemistry — Stanford University
Specialist in HPLC and mass spectrometry
GMP certification — European Medicines Agency
SCIENTIFIC LIBRARY
Research, standards, and regulation
REVIEW
BPC 157 Therapy — Multifunctionality and Medical Application Review
Józwiak et al. · Pharmaceuticals · 2025Review of the studied medical applications and multifunctional mechanisms of BPC 157.
View publication TIDES2024 FDA TIDES Harvest — Peptides and Oligonucleotides
Al Musaimi et al. · Pharmaceuticals · 2025Annual overview of approved and developing peptides and oligonucleotides.
View publication PREPRINTSafety and Efficacy of Peptide Therapies for Musculoskeletal Injuries
Preprints.org · 2025Analysis of the safety and efficacy of peptide therapies for musculoskeletal injuries.
View publication REGULATIONWhat's Changing With Peptide Regulation in 2026 — FDA PCAC Update
BSCG · May 2026Update on regulatory changes and the FDA advisory process in 2026.
View publication FDACGMP Regulations
FDA.govOfficial reference for current good pharmaceutical manufacturing practices.
View publication The United States Pharmacopeial ConventionPeptide Medicines — Standards
United States PharmacopeiaThe United States Pharmacopeial Convention standards and technical resources applied to peptide medicines.
View publication